Related Experiment Video

Updated: Aug 9, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Regulation of STAT3-mediated signaling by LMW-DSP2

Y Sekine1, S Tsuji, O Ikeda

  • 1Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Oncogene
|April 26, 2006
PubMed

Insights

Low molecular weight-dual specificity phosphatase two (LMW-DSP2) negatively regulates the IL-6/STAT3 signaling pathway. LMW-DSP2 suppresses STAT3 activation and IL-6-induced gene expression, indicating its role in cancer cell signaling.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Biochemistry

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is crucial in physiological processes and constitutively active in many cancers.
  • The interleukin 6 (IL-6)/leukemia inhibitory factor (LIF)/STAT3 pathway is implicated in various cellular functions and disease states.

Purpose of the Study:

  • To investigate the role of low molecular weight-dual specificity phosphatase two (LMW-DSP2) in regulating the IL-6/LIF/STAT3 signaling pathway.
  • To determine if LMW-DSP2 acts as a modulator of STAT3 activation and downstream gene expression.

Main Methods:

  • Examined IL-6/LIF-induced LMW-DSP2 expression in murine testicular and hepatoma cell lines.
  • Utilized LMW-DSP2 overexpression in 293T cells and small-interfering RNA (siRNA) to modulate LMW-DSP2 levels.
  • Assessed STAT3 phosphorylation and STAT3-dependent transcriptional activity.
  • Performed co-immunoprecipitation to study in vivo and endogenous interactions between LMW-DSP2 and STAT3.

Main Results:

  • IL-6 and LIF induced LMW-DSP2 expression in tested cell lines.
  • Overexpression of LMW-DSP2 inhibited IL-6-induced STAT3 phosphorylation and activation.
  • LMW-DSP2 suppressed the expression of IL-6-induced endogenous genes.
  • siRNA-mediated knockdown of LMW-DSP2 enhanced IL-6-induced STAT3-dependent transcription.
  • LMW-DSP2 was found to interact with STAT3 both in vivo and endogenously.

Conclusions:

  • LMW-DSP2 functions as a negative regulator of the IL-6/LIF/STAT3 signaling pathway.
  • LMW-DSP2 directly interacts with STAT3, modulating its activity and downstream effects.
  • These findings highlight LMW-DSP2 as a potential therapeutic target in cancers with aberrant STAT3 activation.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...